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Abstract
Background—In contingency management (CM), individuals receive rewards for alcohol 
abstinence. CM is associated with reduced alcohol use in adults with co-occurring serious mental 
illnesses (SMI). Pre-treatment urine ethyl glucuronide (uEtG) levels equivalent to daily heavy 
drinking (uEtG > 349 ng/mL) are associated with poor response to CM. Modifications to CM are 
needed to improve outcomes for non-responders.
Aims—To determine if pre-treatment heavy drinkers, defined by uEtG, with SMI achieve higher 
levels of alcohol abstinence when they receive an increased magnitude of reinforcement for 
abstinence (High-Magnitude CM) or reinforcers for reduced drinking, prior to receiving 
reinforcers for abstinence (Shaping CM), relative to those who receive typical low-magnitude 
abstinence based CM (Usual CM). Additionally, variables in the Addictions Neuroclinical 
Assessment model will be examined as treatment response moderators.
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Methods—Participants (N = 400) will be recruited from two urban mental health organizations 
and complete a 4-week induction period where they will be reinforced for submitting samples for 
uEtG testing. Participants who attain a mean uEtG > 349 mg/mL will be randomized to receive 
either Usual CM, High-Magnitude CM, or Shaping CM for 16 weeks. Differences in abstinence, 
assessed by uEtG, will be examined during treatment and during a 12-month follow-up. Measures 
of negative emotionality, alcohol reinforcer salience, and executive functioning will be gathered at 
study intake and used to predict treatment outcomes.
Discussion—This novel approach to CM will use an alcohol biomarker to identify those at risk 
for treatment non-response and determine if adaptations to CM might improve outcomes for this 
group.
Keywords
Alcohol treatment; Contingency management; Ethyl glucuronide; Serious mental illness 
addictions neuroclinical assessment
1. Introduction
Forty-six percent of individuals with serious mental illnesses ([SMI]; i.e., schizophrenia 
spectrum, bipolar, and recurrent major depressive disorders) have a co-occurring alcohol use 
disorder (AUD) [1–4]. Relative to people with SMI who do not use substances, those who 
use alcohol or drugs experience higher levels of psychotic symptoms, in-patient psychiatric 
care, medical expenditures, homelessness, treatment attrition, suicidal behavior, and 
cognitive impairment [5–14]. Few individuals receive treatment for co-occurring SMI and 
AUDs, and even fewer individuals receive evidenced-based treatments [15,16].
Contingency management (CM) is a behavioral intervention that provides low-cost 
reinforcers (i.e., total of $250–$400) for drug and alcohol abstinence [17] and is associated 
with decreased alcohol and drug use in individuals with SMI [18–21]. In a previous study of 
CM as a treatment for AUD in adults with SMI, we used the alcohol biomarker, urine ethyl 
glucuronide urine (uEtG) to assess abstinence. uEtG can detect use during the previous 2 
days and heavy drinking up to 5 days after drinking [20,22,23]. CM participants were 3.1 
times more likely to submit negative uEtG samples, relative to those receiving treatment-as-
usual (TAU) and reinforcers for participation only [20]. However, participants with a pre-
treatment uEtG > 499 ng/mL (i.e., daily heavy drinking) did not respond to CM [20].
This finding is consistent with other studies that have found that biologically verified drug 
use immediately prior to treatment is associated with poor response to low-cost, abstinence-
based CM [24–27]. Increasing reinforcer magnitude (i.e., high-magnitude CM) is associated 
with improved outcomes, particularly for those who submitted drug-positive urine tests 
immediately prior to CM treatment [17,28–30]. Providing reinforcers for reductions in 
substance use before requiring abstinence (i.e., shaping CM) is also associated with 
improved outcomes for people who smoke cigarettes or use drugs, who do not respond to a 
typical low-cost abstinence-based CM [31–33]. However, no study has investigated the 
effectiveness of these CM adaptions for treating AUDs, or compared these approaches to 
one another.
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While others have investigated predictors of treatment response, no previous study has 
examined predictors of outcomes using a theoretical framework. The Addictions 
Neuroclinical Assessment (ANA) framework, developed by the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA), is a neuroscience-based framework for explaining 
the causes and maintenance of addiction [34]. This framework postulates three domains – 
poor executive functioning (e.g., working memory, impulsivity), negative emotionality (e.g., 
depression, anxiety, psychological symptoms of withdrawal), and high levels of alcohol-
related incentive salience (e.g., thinking about alcohol, craving a drink) –as the primary 
factors that cause and maintain AUDs. This model maybe particularly applicable to heavy 
drinkers with SMI, because these individuals experience high levels of negative emotions, 
poor working memory, and high levels of impulsivity and alcohol-cravings [35,36].
Funded by NIAAA (R01AA020248), we will be conducting a randomized clinical trial to 
determine the following aims: 1) whether levels of alcohol abstinence during the last 3 
months of treatment, and a 12-month follow-up period vary by CM condition; 2) whether 
groups differ on secondary alcohol outcomes, drug use, psychiatric severity, HIV risk 
behavior, and cigarette smoking; and 3) identify ANA-based moderators of CM treatment 
response across and within CM conditions.
2. Methods
2.1. Study design
Participants (N = 400) recruited from two urban mental health organizations will first take 
part in a 4-week induction phase during which they will receive reinforcers for submitting 2 
urine samples per week, regardless of uEtG results. Participants who meet secondary 
eligibility criteria of attendance (estimated N = 240; see below) and uEtG-defined heavy 
drinking (uEtG > 349 ng/mL) will be randomized to receive either, a)4 months of standard-
magnitude reinforcement CM for submitting alcohol-negative samples (uEtG < 150 ng/mL; 
Usual CM); b)4 months of high-magnitude CM for submitting alcohol-negative samples 
(High-Magnitude CM); or c)1 month of standard-magnitude CM for submitting urine 
samples that indicate light drinking (uEtG < 350 ng/mL), followed by 3 months of standard-
magnitude CM for submitting alcohol-negative samples (Shaping CM). Our CM paradigm 
will use the variable magnitude of reinforcement procedure (VMRP), in which participants 
draw from a bowl for chances to receive items and gift cards. Groups will differ only on the 
number of draws they receive (Usual vs. High-Magnitude), or the contingency by which they 
are allowed to engage in draws (light drinking vs. abstinence).
Randomized participants will complete follow-up assessments at 1, 3, 6, and 12 months to 
assess long-term outcomes. The primary outcome will be alcohol abstinence, assessed as 
uEtG < 150 ng/mL, during the last 3 months of treatment (when all reinforcers are 
contingent on abstinence) and the 12-month follow-up period.
2.2. Study procedures
2.2.1. Participant eligibility—Inclusion criteria include the following: 1) 4 or more 
standard drinks on 5 or more occasions in the past 30 days; 2) Diagnostic and Statistical 
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Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of moderate to severe AUD 
[37]; 3) DSM-5 diagnosis of schizophrenia or schizoaffective, bipolar I or II, or recurrent 
major depressive disorder (> 1 episode); 4) age 18–65 years; and 5) receipt of, or eligibility 
to receive TAU at study sites. Exclusion criteria include the following: 1) current DSM-5 
diagnosis of a severe drug use disorder; 2) inability to demonstrate competency to provide 
consent on the MacAuthur Competence Assessment Tool for Clinical Research (MacCAT-
CR); 3) risk of medically dangerous alcohol withdrawal (i.e., seizure within the last 12 
months, concern by participant or clinician regarding a potentially dangerous withdrawal); 
4) prior diagnosis of dementia; and 5) determination by the Principal Investigator (PI) and 
medical director that participation would be medically or psychiatrically unsafe.
2.2.2. Randomization procedures—Participants will be randomized to treatment 
conditions based on permuted block randomization and stratified across the following 
variables: 1) study site, 2) gender, and 3) baseline uEtG level > 1000 ng/mL (e.g., > 8 
standard drinks), which indicates very heavy recent drinking.
2.3. Induction phase
Eligible participants will take part in a 4-week induction phase, during which they will 
engage in the VMRP procedure 2 times a week for providing urine samples. At each visit, 
they will receive 3 draws for prizes when they provide urine samples, regardless of whether 
the samples are positive for alcohol use. Those who provide at least 1 urine sample during 
each of these 4 weeks will receive a $20 bonus incentive. Consistent with previous studies 
[38] participants who 1) attain an average uEtG level of > 349 ng/mL (indicating recent 
heavy drinking) and 2) attend at least 1 study visit during the final week of the induction 
phase will be randomized. Participants who do not meet criteria for randomization will be 
referred to other available AUD treatments (See Fig. 1). Although our published research 
demonstrates that uEtG > 499 ng/mL is associated with poor treatment response [20], 
unpublished analyses suggested that a lower cut-off of uEtG > 349 ng/mL predicts poor 
treatment response similar to a uEtG cut-off > 499 ng/ mL. The use of a lower cut-off of 
uEtG > 349 ng/mL cut-off will allow increase the number of potential participants 
randomized into the 3 CM conditions during the treatment phase.
2.4. Study intervention
2.4.1. Treatment-as-usual—All participants will receive psychiatric services and 
addiction TAU. The two urban mental health organizations provide a variety of services at 
multiple locations in their respective cities (Spokane and Seattle, Washington). Case 
management, medication management, group and individual counseling, vocational services 
and housing services will be available to participants based on their individual needs. These 
organizations also offer outpatient addiction treatment and referrals to local addiction 
agencies.
2.4.2. Prize draws—Participants in the 3 CM conditions will engage in VMRP each time 
they meet criteria for obtaining reinforcers over the 16-week treatment phase. Table 1 
illustrates how groups will differ only by the number of times they engage in prize draws 
(Usual CM vs. High-Magnitude CM) or the criterion required to receive reinforcement (light 
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drinking vs. abstinence). VMRP will involve drawing from a bowl of 500 chips, some of 
which represent prizes with different dollar amounts. Twenty-five percent will say “good 
job” (no prize), 62.6% will result in a small prize ($1 to $5 value), 12% will result in a large 
prize ($20 to $30 value), and 0.4% will result in a jumbo prize ($80 to $100 value). For each 
urine sample that meets reinforcement criteria, participants will complete the corresponding 
number of draws. The number of drawings will escalate with each full week (2 consecutive 
samples) that meets criteria for reinforcement. Missing samples or samples that do not meet 
reinforcement criteria will result in a reset to the original number of draws (5 draws for 
Usual and Shaping CM, 15 draws for High-Magnitude CM) on the next occasion when the 
participant provides a sample that meets reinforcement criteria. If a reset occurs, participants 
must provide 2 consecutive samples that meet reinforcement criteria before they are returned 
to the number of draws they previously accumulated. This procedure reduces the probability 
of relapse after abstinence is initiated [39].
2.4.3. Usual CM condition—Participants randomized to the Usual CM condition will 
earn at least 5 prize draws each time they submit an alcohol-negative urine sample (uEtG < 
150 ng/mL), and an additional draw for each week (2 consecutive alcohol-negative samples) 
of abstinence. Continuously abstinent participants will receive 20 draws for alcohol-negative 
tests at each of their week 20 appointments.
2.4.4. High-magnitude CM condition—Participants randomized to this group will be 
required to demonstrate alcohol abstinence (uEtG < 150 ng/mL) to receive reinforcers. 
However, they will receive twice as many prize draws overall relative to the Usual CM group 
for submitting alcohol-negative samples during the 16-week treatment phase, since they will 
earn at least 15 draws for each negative sample. Note that, although the initial number of 
draws in the High-Magnitude group is 3 times higher than in the Usual CM group, the 
difference in the number of draws will become less pronounced over the 16-week treatment 
phase, and will ultimately approximate twice as many chances to engage in prize draws. One 
additional draw will be accumulated for each 2 continuous alcohol-negative samples of 
abstinence. Continuously abstinent participants will be able to earn 30 draws for alcohol-
negative samples at each appointment in week 20.
2.4.5. Shaping CM condition—Participants randomized to the Shaping condition will 
receive the same number of prize draws as those in the Usual CM condition. However, 
during the first 4 weeks of treatment (weeks 5–8), participants will engage in prize draws for 
light drinking (uEtG < 500 ng/mL) rather than abstinence. Although the uEtG cutoff of 500 
ng/mL is higher than the 350 ng/mL required for randomization, the possibility of 
individuals increasing their level of drinking and receiving reinforcements in the Shaping 
treatment condition is offset by results from our previous study that heavy drinkers who had 
EtG levels that were above 500 ng/mL during the induction period. Additionally our work 
suggests that the cutoff of 500 ng/mL is most consistently associated with recent heavy 
drinking a clinically significant treatment target [22]. During the final 3 months of treatment 
(weeks 9–20) participants will receive prize draws for alcohol abstinence (uEtG < 150 ng/
mL). Participants will earn at least 3 draws for each urine sample indicating no heavy 
drinking during weeks 5–8 and no alcohol use at all during weeks 9–20. An additional draw 
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will be accumulated for each consecutive week (2 consecutive samples) in which 
participants meet all criteria for receiving reinforcers. Those who continuously meet criteria 
for reinforcers will be able to earn 20 draws at each of their week 20 appointments.
2.5. Data collection
Data collection will occur during the study (weeks 1–20, including baseline assessment, 
induction, and treatment) and the follow-up periods (weeks 21–71). Baseline data collection 
will take ~120 min and include urine tests, self-reported data, and cognitive tests. 
Participants will provide urine samples twice a week during the study period. At each visit, 
they will complete brief self-report questionnaires assessing alcohol use. Weeks 4, 8, 12, 16, 
and 20 will include 45-minute data collection visits to assess other outcomes. During follow-
up, participants will be scheduled for 45-minute visits at weeks 25, 33, 47, and 71. 
Participants will receive a $30 gift card for completing the baseline interview and a $20 gift 
card for completing each interview in weeks 4, 8, 12, 16, 20, 25, 33, 47, and 71 (see Fig. 1).
2.6. Measures
2.6.1. Alcohol and drug biomarkers—At each study visit, urine samples will be 
collected and analyzed onsite for uEtG by using the uEtG immunoassay on an Indiko Bench 
Top Analyzer (ThermoFischer Scientific, Freemont, CA). An assay will be created for a 
binary indicator of alcohol use defined by uEtG < 150 ng/ mL. Recent heavy drinking will 
also be assessed by uEtG tests with a cut-off of uEtG > 349 ng/mL during the indication 
phase and a cut-off of uEtG > 499 ng/mL for participants randomized to the Shaping CM 
condition [22]. Although the use of alcohol-containing products has not been associated with 
false positives [22,40], participants will be asked to abstain from using all alcohol-
containing products (i.e., hand sanitizer). Urine samples will be tested for opioids (morphine 
> 2000 ng/ mL), amphetamine (D-amphetamine > 1000 ng/mL), methamphetamine (D-
methamphetamine > 1000 ng/mL), cocaine benzoylecgonine > 300 ng/mL, and cannabis 
(tetrahydrocannabinol > 50 ng/mL) with EZ-split point-of-care immunoassays at each study 
visit.
2.6.2. Self-report alcohol use—Days of self-reported abstinence and heavy drinking 
will be assessed at each visit using the Alcohol Timeline FollowBack [41], which measures 
the frequency and amount of daily drinking. The Addiction Severity Index Lite will assess 
the impact of alcohol use on psychiatric, legal, medical, and family functioning, as well as 
self-reported drug use and its severity [42]. We will assess alcohol cravings by using a 10 cm 
visual analog scale anchored at 0 (no craving) and 100 (most intense craving possible). The 
Stages of Change Readiness and Treatment Eagerness Scale will be administered to measure 
of motivation to change alcohol use [43].
2.6.3. Psychiatric symptoms—The Positive and Negative Syndrome Scale (PANSS) 
[44] will be used to monitor the clinician-rated severity of positive (e.g., hallucinations) and 
negative (e.g., avolition) symptoms of schizophrenia-type illness, as well as mood and 
anxiety symptoms.
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2.6.4. ANA framework—At baseline and weekly during the induction phase, the NIH 
Toolbox Emotion battery will be administered using computerized adaptive testing to 
measure negative emotionality (anger, fear, sadness), psychological well-being, stress and 
self-efficacy, and social relationships. At baseline, the NIH Toolbox Cognition battery will 
be completed and includes measures of executive functioning, episodic memory, processing 
speed, working memory, and attention. These comprise the Fluid Cognition Composite 
Score, our primary measure of executive functioning from the ANA framework. The 
Monetary Choice Questionnaire (MCQ), a delayed discounting measure from the PhenX 
Toolkit will also be used to supplement the Cognitive battery [45]. Alcohol-related incentive 
salience will be measured with the Obsessive-Compulsive Drinking Scale, a self-report 
measure of frequency and consequences of alcohol-related thoughts and behaviors [46], and 
the Stimulus-Response Compatibility Task, a performance-based measure of approach-
avoidance of alcohol-related cues [47].
2.6.5. Other outcome measures—The Timeline FollowBack method will assess the 
number of cigarettes smoked daily [41]. The Fagerstrom Test of Nicotine Dependence will 
assess the presence and severity of nicotine dependence [48]. HIV risk behavior will be 
assessed with the brief HIV Risk Behavior Scale [49].
2.7. Adverse events
A determination of the association of any adverse event with the study intervention will be 
made, and appropriate modification of the protocol will be executed if an association is 
suspected. If protocol modifications to ensure the safety of future study participants cannot 
be executed, the study will be terminated. In the case of a potential serious adverse event, all 
study procedures and enrollment will be stopped until an investigation conducted by the PI 
and Co-Investigators has occurred. The PI will determine whether the event should be 
classified as “serious” or not by using standard US Food and Drug Administration 
guidelines for a serious adverse event. All adverse events will be reported to the Institutional 
Review Board (IRB), Data Safety Monitoring Board, Partnering Agency Leadership, and 
National Institute of Health. Non-serious events will be reported to the Data Safety 
Monitoring Board quarterly and to the program official and IRB annually.
3. Analytic plan
3.1. Preliminary analyses
Groups will be compared for differences in demographics, and pre-treatment drug and 
alcohol use, including data collected during the baseline interview and the 4-week induction 
phase. Baseline comparisons will use analysis of variance (ANOVA) for continuous 
variables and chi-square tests for categorical variables. We do not anticipate differences 
between the two groups that will need to be accounted. However, variables that differ 
between groups at baseline and during the induction phase will be used as covariates in 
subsequent analyses, as will baseline measures that co-vary with the outcome measures. This 
is a strategy of preliminary analysis that we and several other teams in the area of CM and 
addiction treatment have utilized for several decades [20,21,23,50–53].
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3.2. Primary analyses
Analyses will be conducted on the intent-to-treat sample (N = 240). Recent alcohol use will 
be documented by using urine test results (binary outcome: uEtG < 150 ng/mL or uEtG > 
149 ng/mL) and analyzed using generalized estimating equations (GEE) with the 
autocorrelated working matrix, generalized regression, and Cox proportional hazard 
regression techniques. GEE models will be used to evaluate the differential change in 
primary (i.e., uEtG) and secondary outcomes (i.e., drug biomarkers, self-report alcohol and 
tobacco use, psychiatric symptoms, HIV risk behavior) by study condition over the 18-
month study period (1 month before the baseline interview plus the 1-month induction, 4-
month treatment, and 12-month follow-up periods), and whether condition interacts with 
change over time. This approach also allows us to characterize between-group differences in 
longitudinal outcomes. For GEE, we will utilize the autoregressive working correlation 
matrix. This has been used effectively in our previous work wherein we have many 
assessments (> 20) on a biochemical outcome, and the assessments are equally spaced. This 
matrix accounts for the fact that urine assessments made closer in time are more highly 
correlated, and those that are farther apart are less highly correlated. For the Cox 
proportional hazards regression, we will examine the outcome of time to relapse in a manner 
consistent with our analysis of uEtG. That is, we will examine the impact of CM condition 
assignment on time to relapse and as necessary, included other covariates that are not 
balanced across the two groups. This will answer the question of which of the three groups 
are at greatest versus least risk of relapse during the treatment period.
Other outcome measures will be derived from recent alcohol use, such as 1) alcohol use 
(yes/no) over time; 2) longest duration of abstinence; 3) total number of periods of alcohol 
abstinence; 4) time to first alcohol abstinence; 5) time to relapse after a specified period of 
alcohol abstinence; and 6) frequency of heavy drinking. GEE will be used to examine these 
outcomes across time, CM condition, and the CM condition-by-time interaction to determine 
whether one condition is superior to the others in promoting discontinuation of alcohol use. 
We will also use descriptive analyses (i.e., mean, SD) across CM condition to determine the 
mean number of heavy drinking days, mean number of longest duration of drug abstinence, 
and mean HIV risk score.
ANA moderators (executive functioning, negative emotionality, alcohol-related incentive 
salience) will be examined to determine whether they interact with CM regardless of 
condition.
This will help us determine whether a given moderator significantly modifies the impact of 
CM on alcohol abstinence. First, we will create an interaction term of CM condition by the 
moderator in question and examine whether the interaction is significant. Second, if the 
interaction is significant, we will examine whether the outcome varies within each CM 
condition across 3 categories of the moderator in question: 1) Mean ± 1 standard deviation, 
2) > 1 standard deviation, and 3) < 1 standard deviation. This will be accomplished by 
conducting a planned linear trend analysis for each CM condition, since we hypothesize that, 
for example, more executive dysfunction will produce worse treatment outcomes [54,55]. 
We would expect this to be true in each of the three CM conditions, but would necessarily be 
more steep in the conditions that showed a stronger effect of CM and hence, a strong and 
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statistically significant linear trend. If a clearer clinical interpretation is needed, we will use 
centering (i.e., subtracting the mean from all participant values on the measure) on the ANA 
moderator being examined, which is consistent with current expert recommendations [54]. 
We will also evaluate sex as a biological variable by investigating whether sex moderates 
treatment outcomes.
3.3. Power
Our choice of sample size for randomization (N = 240) is based on statistical power 
calculations for the primary aim of reducing alcohol use and the secondary aim of improving 
other outcomes during the final 3 months of the intervention and the 12-month follow-up 
period. We estimated power by using clinically significant cut-off estimates in conjunction 
with previously reported effect sizes of adapted CM interventions [56,57], based on a sample 
size of 180, (60 per group), to adjust for an estimated attrition of 25% of the randomized 
sample (N = 240). All power analyses used an alpha threshold for statistical significance of p 
< 0.05 and utilized two-tailed tests to remain conservative, despite our one-tailed 
hypotheses. Power analyses for specific aims 1 and 2 are based on outcome measures (i.e., 
binary and continuous). Binary measures will have at least 85% power to detect an odds 
ratio of 1.36 (or a 7%, relative difference) between the three treatment groups. This analysis 
assumes 36 assessments across the 12 weeks of treatment and an average correlation 
between the assessments of r = 0.3. Continuous measures will have at least 99% power to 
detect a 50% mean reduction in measures of continuous alcohol use (e.g., heavy drinking 
days) between treatment groups with the same assumptions at work. We will also maintain 
at least 99% power to detect a 50% mean decrease in continuous alcohol use measures (e.g., 
heavy drinking days) when conducting our planned comparisons after our initial, omnibus 
test with the same assumptions at work.
3.4. Missing data
We have developed extensive tracking procedures to reduce missing data, which will be 
handled in a manner consistent with current expert recommendations, some of which our 
team has contributed to [21,25,58–60]. Maximum likelihood or multiple imputation 
“missing not at random” approaches, We will utilize missing at random approaches in 
combination with GEE in order to overcome the problematic default of GEE’s procedure for 
handling missing data. These approaches are preferable to other data imputation approaches, 
such as mean imputation or positive value (i.e., assuming the individual in question drank 
alcohol because they were missing) imputation [61]. Importantly, treatment assignment 
along with several other relevant covariates will help during the imputation process, or the 
altered estimation process if maximum likelihood is used, to optimize the accounting for 
missing data, regardless of differential dropout between the groups.
Lastly, extensive sensitivity analyses will be utilized which include examination of the 
robustness of treatment effects under varying assumptions, e.g., assumption of “missing 
completely at random”. As we have done previously [21], if necessary, we will explore the 
1) Wu-Carroll selection model, 2) Diggle-Kenard selection model, and the 3) pattern-
mixture model. A detailed methodological description of these models and how to conduct 
them can be found in Enders et al., 2011 and McPherson et al., 2014 [60,62].
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4. Discussion
CM is associated with reduced alcohol use in adults with co-occurring SMI. However, heavy 
drinkers, as identified by uEtG, do not respond to typical low-cost abstinence-based CM. 
Increasing the magnitude of reinforcement, and reinforcing reduced drinking prior to 
requiring abstinence, are two promising strategies for non-responders. To our knowledge, 
this is the first study to compare these two strategies to a typical CM intervention in a 
sample of likely non-responders.
NIAAA proposed the ANA model as a method for conceptualizing the causes of and factors 
that maintain addiction, as well as a strategy to develop new treatments. Therefore, we will 
utilize this framework to identify potential predictors of CM treatment response across and 
within CM interventions. Investigating the ANA model in a sample of heavy drinkers 
diagnosed with co-occurring SMI, is particularly relevant as these individuals are likely to 
have high levels of mood dysregulation, impaired executive functioning disorders, and 
alcohol-related incentive salience. Therefore, this study offers a unique opportunity to 
determine if certain subgroups, as defined by ANA variables, respond differentially to the 
study interventions.
The overall goal of this program of research is to develop a personalized medicine approach 
to the treatment of AUDs in adults with SMI. Given the heterogeneity of this population in 
terms of AUD and SMI severity, it is likely that effectiveness will vary by intervention and 
participant subgroup. If reliable methods, such as uEtG tests or assessments of the ANA 
model, can be used to identify these subgroups, then clinicians could use these tools to 
personalize interventions for specific populations, which could have important clinical and 
policy implications.
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Fig. 1. 
Overview of study procedures.
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Table 1
Summary of Contingency Management (CM) schedules and maximum earnings for randomized groups.
Contingency Management group Criteria for reinforcement
Maximum # of prize 
draws Maximum/expected payout
Usual uEtG < 150 ng/mL (abstinence) in weeks 5–20 400 $1370/$500
High-magnitude uEtG < 150 ng/mL (abstinence) in weeks 5–20 720 $2411/$1000
Shaping uEtG < 500 ng/mL (light drinking) in weeks 5–8 400 $1370/$500
uEtG < 150 ng/mL (abstinence) in weeks 9–20
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